Dr. Peter R. Graze

Nirmish Singla is an Oncologist in Lutherville, Maryland. Dr. Singla is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Renal Cell Carcinoma (RCC), Urothelial Cancer, Nephrectomy, and Orchiectomy.

Dr. Michael A. Carducci is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine. He serves as the Vice Chair of Solid Tumor Oncology in the Department of Oncology. Dr. Carducci has an expertise in various types of cancer including prostate, kidney, and testicular. He also has an expertise in clinical trials, pain and palliative care for oncology, urological oncology, urology and medical oncology. A graduate of Georgetown University, Dr. Carducci received his medical degree with high distinction from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at Johns Hopkins Hospital. He was promoted to Professor of Oncology and Urology in 2008 and installed into the inaugural AEGON Professorship in Prostate Cancer Research in 2009. He served as Co-Director of the GU Oncology program until 2013. In 2013, he assumed the leadership role of Associate Director for Clinical Research until being named Vice-Chair of Solid Tumor Oncology in 2024. A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology, Dr. Carducci has received peer-reviewed funding for his clinical research from the National Cancer Institute, Department of Defense, and the Prostate Cancer Foundation. Mentorship of students, fellows, and junior faculty has been another focus of Dr. Carducci’s career in medicine, receiving numerous teaching awards. Dr. Carducci received the Michaele Christian Award and Lectureship for Oncology Drug Development at the National Cancer Institute in 2011. He chaired the Genitourinary Oncology Committee of ECOG-ACRIN from 2011-2024. In this role, he served on the GU Steering Committee for the NCI. Dr. Carducci is a member of the Investigational Drug Steering Committee for the NCI, and chaired that Committee for four years. He served as Associate Editor for GU Cancers for the Journal of Clinical Oncology from 2013-2024. Overall, his clinical research focus is on the development and evaluation of new therapies for urologic cancers. Incorporation of pharmacodynamics, novel biomarkers, and targeted imaging has been key elements of many of the trials led by Dr. Carducci. To complete these studies, Dr. Carducci facilitates and brings together a multidisciplinary team from urologists, radiation oncologists, pathologists, biostatisticians, and medical oncologists. Other areas of interest include palliative and end of life care, survivorship, and use of patient reported outcomes in clinical research and care. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Carducci is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Orchiectomy.

Dr. Mohamad Allaf is Professor of Urology and Oncology, as well as Director of the Department of Urology and the Brady Urological Institute and Urologist-in-Chief of the Johns Hopkins Hospital. Dr. Allaf is a world renowned surgeon-scientist having performed more than 2,000 robotic procedures and published over 250 peer reviewed research papers in the field's best journals. As one of the busiest robotic radical prostatectomy surgeons in the world, he aims to achieve the best outcomes for his patients. Having trained with Dr. Patrick Walsh, Dr. Allaf has used Dr. Walsh's method of radical prostatectomy as the basis for his own anatomic method to this complex operation. Dr. Allaf is also amongst the leaders in kidney cancer surgery, having served on the American Urological Association Guideline Committee for Kidney Cancer. He led a team who performed the rigorous analysis to help inform the most recent guidelines that was funded by the Agency for Healthcare Research and Quality (AHRQ). He is best known for his ability to save the kidney and remove the tumor in patients with kidney tumors. Dr. Allaf runs a research endeavor aiming to decrease the morbidity associated with the treatment of cancer, and he has mentored numerous leaders in academic urology. He is actively involved in fund raising for research and education, and believes in expanding our base of support in order to advance our important mission. Dr. Allaf is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Renal Cell Carcinoma (RCC), Renal Oncocytoma, Prostate Cancer, Nephrectomy, and Prostatectomy.